9/16/2013

The FDA granted fast-track designation to Synta Pharmaceuticals' ganetespib, which is being developed as a therapy for metastatic nonsmall-cell lung adenocarcinoma. The drug, a heat shock protein 90 inhibitor, is in a midstage and late-stage trial program.

Related Summaries